Business
Will Crude Oil Become Cheaper Than Water? Experts See A Massive Price Fall By March 2027
New Delhi: Crude oil prices in the international market could soon fall below the cost of a bottle of drinking water, and this is not an exaggeration. According to projections by global brokerage giant JP Morgan, Brent crude could drop to $30 per barrel by March 2027.
If converted to Indian rupees at an estimated exchange rate of Rs 95 per dollar, the price of one barrel would come to roughly Rs 2,850. Given that a barrel contains 159 litres, this would bring the cost of one litre of crude to just Rs 17.90, cheaper than the average price of bottled water in Delhi, which presently ranges between Rs 18 and Rs 20 per litre.
A Major Price Drop
JP Morgan’s forecast is significant for countries that rely heavily on crude imports. The firm estimates that Brent crude could fall more than 50% from present levels, which are hovering just above $62 per barrel. The expected decline is primarily due to a surge in global supply that could exceed demand.
Even though global oil consumption is projected to rise steadily over the next three years, supply growth, particularly from non-OPEC+ countries (Russia, Mexico, Kazakhstan, Oman, Malaysia, Sudan & South Sudan, Azerbaijan, Bahrain, Brunei and Singapore), is expected to outpace demand. This supply glut is likely to put considerable downward pressure on prices.
Global Demand, Supply Dynamics
In 2025, global oil demand is expected to grow by 0.9 million barrels per day (mbpd), reaching a total consumption of 105.5 mbpd. Growth is predicted to remain steady in 2026 and could rise to 1.2 mbpd in 2027.
However, JP Morgan forecasts that supply growth will significantly exceed these demand hikes. In 2025 and 2026, supply could expand nearly three times faster than demand. By 2027, supply will continue to outpace consumption, creating an oversupply that could depress prices further.
Non-OPEC+ Drives Oil Supply Boom
One of the key drivers of this oversupply will be production from non-OPEC+ countries. JP Morgan highlights that roughly half of the expected supply surplus by 2027 will come from outside the traditional OPEC+ coalition (Saudi Arabia, Iraq, UAE, Kuwait, Iran, Venezuela, Nigeria, Libya, Algeria, Angola, Gabon, Republic of the Congo and Equatorial Guinea), fuelled by steady offshore growth and global shale production.
Once considered a high-cost cyclical sector, offshore oil has now become a reliable low-cost growth engine. JP Morgan projects offshore additions of 0.5 mbpd in 2025, 0.9 mbpd in 2026 and 0.4 mbpd in 2027.
Most floating production, storage and offloading (FPSO) units required for this expansion have already been approved, making this growth highly probable.
Shale, Other Key Supply Sources
Shale oil remains the most flexible lever in global supply. While US shale growth is slowing, efficiency and productivity improvements continue to support output. In addition, Argentina’s Vaca Muerta region has emerged as a low-cost scalable source thanks to improvements in export infrastructure.
Global shale supply is expected to increase by 0.8 mbpd in 2025. Assuming prices remain around $50 per barrel, production could grow by another 0.4 mbpd in 2026 and 0.5 mbpd in 2027. This surge in supply has already contributed to a rise in global inventories, which increased by 1.5 mbpd this year alone, including roughly 1 mbpd in floating storage and Chinese stockpiles.
JP Morgan expects this surplus layer to continue through 2026, with inventories potentially reaching 2.8 mbpd in 2026 and 2.7 mbpd in 2027 if no supply adjustments are made.
How $30 Per Barrel Could Happen
This imbalance could push Brent crude below $60 in 2026, possibly dropping to around $50 in the final quarter of the year. Average prices could fall to $42 by 2027, with end-of-year levels approaching $30 per barrel.
While supply cuts could be used to stabilise prices, hitting $30 would be challenging. The forecast suggests Brent could trade around $58 per barrel in 2026, slightly below current levels above $60.
Impact On Petrol, Diesel Prices In India
Such a dramatic fall in crude prices would be a major benefit for India. Petrol and diesel prices could drop substantially, easing the burden on consumers.
At present, Brent crude imports cost India over Rs 5,600 per barrel due to both price and rupee depreciation. By 2027, even if the rupee weakens to Rs 100 per dollar, the cost per barrel would still fall to around Rs 3,000 (roughly Rs 2,600 cheaper than current levels).
This provides ample room for the government and oil companies to reduce retail fuel prices.
Home sales made a small gain to start the year, but higher mortgage rates now could throw cold water on the spring season.
Existing home sales in February rose 1.7% from January to a seasonally adjusted, annualized rate of 4.09 million units, according to the National Association of Realtors. Sales were down 1.4% from February of last year.
This count represents closed sales, so deals were likely inked in December and January, when mortgage rates fell a bit and stayed solidly in a low range near 6% on the 30-year-fixed mortgage. Rates were about a full percentage point higher the year before.
“Despite the modest gain in home sales, actual housing demand remains muted relative to wage growth and job gains,” Lawrence Yun, chief economist for the Realtors, said in a release. “Wage growth is now outpacing home price growth by almost four percentage points. Mortgage rates are also measurably lower compared to a year ago.”
Yun also noted that there are over 6 million more jobs now than there were in 2019, yet home sales per year are down by 1 million.
Lower mortgage rates helped improve affordability slightly, but low inventory is still a significant headwind. There were 1.29 million units for sale at the end of February, an increase of 2.4% from January and 4.9% from February 2025. At the current sales pace, that is a 3.8-month supply, unchanged from January. A six-month supply is considered a balanced market between buyer and seller.
More sellers who delisted their homes last fall, due to slower sales and weak consumer confidence, are relisting their homes now, according to Redfin, a real estate brokerage. Nearly 45,000 homes that were delisted last year were relisted for sale in January. That is the highest January figure since Redfin began tracking this metric a decade ago and represents a record 3.6% of homes that were on the market in January.
“Inventory is growing, but sluggishly,” Yun said. “If demand picks up notably in the coming months and outpaces supply growth, home prices will inevitably rise. That is why increasing supply is so important to help limit home price growth, improve housing affordability, and boost transactions.”
Tight supply, however, is keeping prices just barely higher. The median price of a home sold in February was $398,000, an increase of 0.3% year over year. Sales continue to be strongest in the highest price category, properties listed at $1 million or above. Sales were down sharply on the lowest end of the market.
It continues to take longer to sell a home, at 47 days, up from 42 days one year ago. First-time buyers represented 34% of total sales, an increase from 31% a year ago. Investors made up 16% of sales, unchanged from a year ago.
Business
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children.
The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism spectrum disorder symptoms. The claim sparked skepticism among some in the medical and research community, but fueled excitement among families, spiking prescriptions of the drug in the U.S.
One FDA official told reporters Monday that “we don’t have sufficient data to say that we could establish efficacy for autism more broadly” but said the agency is open to interest from companies in studying leucovorin in the autism population.
The medication, also referred to as folinic acid, is a synthetic form of vitamin B9 that has been used to treat the toxic side effects of chemotherapy. Just a handful of small trials have suggested that leucovorin could be effective as an off-label treatment for children with autism, and some families have reported that it helped their nonverbal kids develop more language and social skills.
FDA officials, who requested anonymity to discuss the decision, told reporters Monday that they started with a broad review of leucovorin as an autism treatment before narrowing its approval to a smaller population with cerebral folate deficiency, a rare genetic mutation that prevents folate – a key vitamin – from properly reaching the brain.
The condition shares overlapping features with autism, typically develops in young children under age 2 and can cause severe developmental delays, seizures, a lack of muscle control and other serious neurological complications.
The officials said the FDA found that using leucovorin in patients with that condition produced the “highest quality data” to support an expanded approval, which will apply to both generic versions of the drug and GSK’s old branded medication, Wellcovorin.
“That was the data where we saw the largest effect sizes,” one FDA official said on the call. “So we narrowed in on that population, just because we felt like that was the strongest both scientific rationale and also the largest treatment effects that could be used to then overcome some of the limitations in the data sources.”
The approval was based on a systematic review of published literature on the area, including patient case reports, but not a randomized controlled clinical trial. The same official acknowledged there can be biases with systematic reviews, but emphasized that the treatment effects were so large that they outweighed those concerns.
The FDA is encouraging existing manufacturers of leucovorin to increase production to match higher demand for the drug, the officials added. While GSK originally marketed the drug from 1983 until 1997, the company said in September that it has no plans to relaunch and manufacture the product itself.
In a release Tuesday, Dr. Tracy Beth Hoeg, acting director of the FDA’s Center for Drug Evaluation and Research, said the approval demonstrates the FDA’s commitment to “rapidly identifying effective treatments for ultra rare diseases while maintaining the same evidentiary standards for approval.”
Pete Hegseth Is Pushing Defense Employees to Volunteer With DHS
White House contradicts claim of US Navy escort in Hormuz Strait
White House contradicts claim of US Navy escort in Hormuz Strait
-
Politics4 days agoIndia let Iran warship dock the day US sank another off Sri Lanka, say officials
-
Sports4 days agoPakistan set for FIH Pro League debut | The Express Tribune
-
Entertainment3 days agoHarry Styles kicks off new era with ‘One Night Only’ comeback show
-
Business4 days agoRestaurant group changes name after bid to buys pubs across the UK
-
Business1 week agoLabour parliamentarians urge UK Government to oppose Rosebank oil field
-
Business4 days agoHome heating oil: ‘Most of my pension has gone on home heating oil’
-
Sports4 days agoWinners and losers of the 2026 NHL trade deadline
-
Sports1 week agoUSA vs. Argentina (Mar 1, 2026) Live Score – ESPN